4[2]Luzzatto G, Cordiano I, Patrassi G, et al. Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use. Thromb-Haemost, 1996, 75( 1 ): 211.
5[3]Rodprasert P. Low molecular weight heparine treatments in cerebral infarctions in gocase. Cerebrovase Dis, 1996,2: 135.
6[4]Laporte S, Mismetti P, Piquet P, et al. Population pharmacokinetic of nadroparin calcium(Fraxiparine) in children hospitalised for open heart surgery. Eur-J-PharmSci, 1999, 8(2): 119.
7[6]Abrial D, Blanc A, Rehailia M, et al. Establishing the dose-dependent daily variations of a low molecular weight heparin(Fraxiparine) through a population approach analysis in the rat. C hronobiol-Int, 2000, 17 (2): 173.
